BR112015012711A2 - método de produção de uma vacina de mycoplasma - Google Patents

método de produção de uma vacina de mycoplasma

Info

Publication number
BR112015012711A2
BR112015012711A2 BR112015012711A BR112015012711A BR112015012711A2 BR 112015012711 A2 BR112015012711 A2 BR 112015012711A2 BR 112015012711 A BR112015012711 A BR 112015012711A BR 112015012711 A BR112015012711 A BR 112015012711A BR 112015012711 A2 BR112015012711 A2 BR 112015012711A2
Authority
BR
Brazil
Prior art keywords
mycoplasma
individual
immunogenic composition
production
relates
Prior art date
Application number
BR112015012711A
Other languages
English (en)
Other versions
BR112015012711B1 (pt
Inventor
V Iyer Arun
Neubauer Axel
Thomas Martinson Brian
Margaret Muehlenthaler Christine
M Murphy Jordan Dianna
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015012711(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of BR112015012711A2 publication Critical patent/BR112015012711A2/pt
Publication of BR112015012711B1 publication Critical patent/BR112015012711B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "método de produção de uma vacina de mycoplasma". a presente invenção refere-se a um método para a preparação de uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma em um indivíduo, o qual compreende o cultivo de bactérias de mycoplasma em um sistema de células eucarióticas com soro reduzido ou livre de soro de suíno; a obtenção de um antígeno das bactérias de mycoplasma; e a adição de um carreador farmaceuticamente aceitável. além disso, a presente invenção refere-se à composição imunogênica que pode ser obtida pelo dito método e a um método para a imunização de um indivíduo que compreende a administração da dita composição imunogênica a um indivíduo.
BR112015012711-8A 2012-12-28 2013-12-20 Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma BR112015012711B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746997P 2012-12-28 2012-12-28
US61/746,997 2012-12-28
PCT/US2013/076807 WO2014105672A1 (en) 2012-12-28 2013-12-20 Method of making a mycoplasma vaccine

Publications (2)

Publication Number Publication Date
BR112015012711A2 true BR112015012711A2 (pt) 2017-07-11
BR112015012711B1 BR112015012711B1 (pt) 2022-08-16

Family

ID=49917778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012711-8A BR112015012711B1 (pt) 2012-12-28 2013-12-20 Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma

Country Status (23)

Country Link
US (2) US9273281B2 (pt)
EP (1) EP2938747B1 (pt)
JP (2) JP6122146B2 (pt)
KR (1) KR102153275B1 (pt)
CN (2) CN104968365B (pt)
AR (1) AR094648A1 (pt)
AU (1) AU2013370983B2 (pt)
BR (1) BR112015012711B1 (pt)
CA (1) CA2896298C (pt)
CL (1) CL2015001562A1 (pt)
DK (1) DK2938747T3 (pt)
EA (1) EA032772B1 (pt)
ES (1) ES2738100T3 (pt)
HU (1) HUE045015T2 (pt)
MX (1) MX361273B (pt)
MY (1) MY173223A (pt)
PH (1) PH12015501333A1 (pt)
PL (1) PL2938747T3 (pt)
PT (1) PT2938747T (pt)
SG (2) SG11201505089YA (pt)
TW (2) TWI660736B (pt)
UA (1) UA121193C2 (pt)
WO (1) WO2014105672A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
WO2014105671A1 (en) * 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
WO2014105672A1 (en) * 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
US10222383B2 (en) 2016-01-29 2019-03-05 Advanced Animal Diagnostics, Inc. Methods and compositions for detecting mycoplasma exposure
RU2724549C1 (ru) * 2016-08-09 2020-06-23 Эгрикалчурал Текнолоджи Рисерч Инститьют Композиция для профилактики и лечения инфекции mycoplasma hyorhinis и способ получения указанной композиции
WO2018144909A1 (en) * 2017-02-03 2018-08-09 The Administrators Of The Tulane Educational Fund Ophthalmic compositions for therapeutic and prophylactic uses
JP6828745B2 (ja) 2017-05-24 2021-02-10 三菱ケミカル株式会社 シートモールディングコンパウンド、繊維強化複合材料および繊維強化複合材料の製造方法
JP2022536410A (ja) 2019-06-10 2022-08-16 エランコ・ユーエス・インコーポレイテッド Ｍｙｃｏｐｌａｓｍａ培地製剤
CN113201050B (zh) * 2020-08-06 2022-07-22 青岛诺安百特生物技术有限公司 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
GB1074920A (en) * 1965-04-21 1967-07-05 Pfizer & Co C Growth medium for mycoplasma pneumoniae and vaccine production
GB1137306A (en) * 1966-07-11 1968-12-18 Research Corp Inoculum for poultry
JPS5540568B2 (pt) 1972-10-05 1980-10-18
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) * 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO2001064846A1 (en) * 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3402304B2 (ja) * 2000-03-30 2003-05-06 株式会社微生物化学研究所 猫クラミジアワクチンの製造方法
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP1521592A2 (en) 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
ATE412426T2 (de) 2001-07-02 2008-11-15 Pfizer Prod Inc Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
MXPA04001872A (es) 2001-08-28 2004-06-15 Pfizer Prod Inc Modelo de exposicion a micoplasma bovis, procedimiento para administrar m. bovis y procedimientos para inducir lesiones pulmonares neumonicas.
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
WO2006084364A1 (en) 2005-02-09 2006-08-17 Magna International Inc. Method of manufacturing a semi-structural panel
WO2006095431A1 (ja) * 2005-03-10 2006-09-14 Kyoritsu Seiyaku Corporation 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法
WO2007042827A2 (en) * 2005-10-14 2007-04-19 Ivan Petyaev Treatment and diagnosis of obligate intracellular pathogens
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
EP2217271B1 (en) * 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
US20090317423A1 (en) 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
WO2009142086A1 (ja) 2008-05-23 2009-11-26 学校法人久留米大学 マイコプラズマ感染症用ワクチン組成物
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
NZ591950A (en) 2008-10-31 2012-12-21 Boehringer Ingelheim Vetmed Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
EA021102B1 (ru) 2009-05-19 2015-04-30 Байопропертис Пти Лтд. Температурочувствительный вакцинный штамм mycoplasma hyopneumoniae и его применения
US20110150770A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
US8112663B2 (en) 2010-03-26 2012-02-07 Lsi Corporation Method to establish redundancy and fault tolerance better than RAID level 6 without using parity
CN102258776B (zh) 2011-07-07 2013-07-10 普莱柯生物工程股份有限公司 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
WO2014105672A1 (en) 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
WO2014105671A1 (en) 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens

Also Published As

Publication number Publication date
ES2738100T3 (es) 2020-01-20
SG11201505089YA (en) 2015-07-30
CL2015001562A1 (es) 2016-06-24
CN108379571A (zh) 2018-08-10
BR112015012711B1 (pt) 2022-08-16
PT2938747T (pt) 2019-08-01
JP2017145253A (ja) 2017-08-24
CN104968365A (zh) 2015-10-07
KR20150100920A (ko) 2015-09-02
EP2938747B1 (en) 2019-05-01
AU2013370983B2 (en) 2019-09-26
US20160136254A1 (en) 2016-05-19
JP2016508983A (ja) 2016-03-24
PL2938747T3 (pl) 2019-11-29
JP6122146B2 (ja) 2017-04-26
HUE045015T2 (hu) 2019-11-28
EA032772B1 (ru) 2019-07-31
AU2013370983A1 (en) 2015-05-21
KR102153275B1 (ko) 2020-09-09
UA121193C2 (uk) 2020-04-27
MY173223A (en) 2020-01-07
EP2938747A1 (en) 2015-11-04
US20140186394A1 (en) 2014-07-03
TW201832777A (zh) 2018-09-16
MX2015007730A (es) 2015-09-07
EA201500701A1 (ru) 2015-12-30
CA2896298C (en) 2024-01-16
PH12015501333A1 (en) 2015-09-02
CN104968365B (zh) 2018-04-03
JP6449364B2 (ja) 2019-01-09
US9273281B2 (en) 2016-03-01
AR094648A1 (es) 2015-08-19
MX361273B (es) 2018-12-03
SG10201708028VA (en) 2017-10-30
TW201438732A (zh) 2014-10-16
WO2014105672A1 (en) 2014-07-03
TWI660736B (zh) 2019-06-01
TWI618542B (zh) 2018-03-21
CA2896298A1 (en) 2014-07-03
DK2938747T3 (da) 2019-08-05
US10512680B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
BR112015012711A2 (pt) método de produção de uma vacina de mycoplasma
BR112022001185A2 (pt) Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112014019667A2 (pt) formulação de anticorpo abeta
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112014026703A2 (pt) inibidores de dna-pk
BR112014003414A2 (pt) método de produção de níveis fisiológicos e terapêuticos de óxido nítrico através de um sistema de entrega oral
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112017015789A2 (pt) vacina de vírus da influenza suína bivalente
BR112013026661A2 (pt) método de entrega de vacina
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
BR112014015112A2 (pt) inibidores de sialoadesina para o tratamento de doenças causadas por vírus encapsulado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2013, OBSERVADAS AS CONDICOES LEGAIS